We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TERIPARATIDE GH (Generic Health Pty Ltd)
Product name
TERIPARATIDE GH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 (175 working days)
Active ingredients
Teriparatide
Registration type
NCE/NBE
Indication
Teriparatide Lupin, Teriparatide GH, Teriparatide LAPL is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.
Teriparatide Lupin, Teriparatide GH, Teriparatide LAPL is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.